Assessment of the 18F-Labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts

Journal of Nuclear Medicine

Volumn 54, Issue 7, 2013, Pages 1142-1146

  Higuchi, Takahiro ^a,b   Yousefi, Behrooz H ^a,c   Kaiser, Franz ^b   Gärtner, Florian ^a   Rischpler, Christoph ^a   Reder, Sybille ^a   Yu, Ming ^d   Robinson, Simon ^d   Schwaiger, Marcus ^a   Nekolla, Stephan G ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Clinical Research   (United States)

Author keywords

Heart; Imaging; NET; Norepinephrine; PET; Rat; Sympathetic nerve

Indexed keywords

DESIPRAMINE; FLUORINE 18; LMI 1195; N [3 BROMO 4 (3 FLUOROPROPOXY)BENZYL]GUANIDINE F 18; NORADRENALIN; PHENOXYBENZAMINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FLUORINE; FLUOROBENZENE; GUANIDINE DERIVATIVE; N (3 BROMO 4 (3 (18F)FLUORO PROPOXY)BENZYL)GUANIDINE; N-(3-BROMO-4-(3-(18F)FLUORO-PROPOXY)BENZYL)GUANIDINE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG UPTAKE; HEART LEFT VENTRICLE WALL; IN VIVO STUDY; ISOTOPE LABELING; MALE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE STUDY; RADIOCARDIOGRAPHY; RAT; ANIMAL; HEART; HEART MUSCLE; IMAGING; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; NET; PET; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SYMPATHETIC NERVE; TISSUE DISTRIBUTION; WISTAR RAT;

HEART; IMAGING; NET; NOREPINEPHRINE; PET; RAT; SYMPATHETIC NERVE;

ANIMALS; FLUORINE RADIOISOTOPES; FLUOROBENZENES; GUANIDINES; HEART; MALE; METABOLIC CLEARANCE RATE; MOLECULAR IMAGING; MYOCARDIUM; NOREPINEPHRINE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84879917466     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.104232     Document Type: Article

References (34)

1. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33:1058-1066.
2. Higuchi T, Schwaiger M. Noninvasive imaging of heart failure: neuronal dysfunction and risk stratification. Heart Fail Clin. 2006;2:193-204.
3. Higuchi T, Schwaiger M. Imaging cardiac neuronal function and dysfunction. Curr Cardiol Rep. 2006;8:131-138.
4. Nguyen NT, DeGrado TR, Chakraborty P, Wieland DM, Schwaiger M. Myocardial kinetics of carbon-11-epinephrine in the isolated working rat heart. J Nucl Med. 1997;38:780-785.
5. DeGrado TR, Hutchins GD, Toorongian SA, Wieland DM, Schwaiger M. Myocardial kinetics of carbon-11-meta-hydroxyephedrine: retention mechanisms and effects of norepinephrine. J Nucl Med. 1993;34:1287-1293.
6. Rischpler C, Park MJ, Fung GS, Javadi M, Tsui BM, Higuchi T. Advances in PET myocardial perfusion imaging: F-18 labeled tracers. Ann Nucl Med. 2012;26:1-6.
7. Higuchi T, Nekolla SG, Huisman MM, et al. A new 18F-labeled myocardial PET tracer: myocardial uptake after permanent and transient coronary occlusion in rats. J Nucl Med. 2008;49:1715-1722.
8. Huisman MC, Higuchi T, Reder S, et al. Initial characterization of an 18F-labeled myocardial perfusion tracer. J Nucl Med. 2008;49:630-636.
9. Nekolla SG, Reder S, Saraste A, et al. Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. Circulation. 2009;119:2333-2342.
10. Yu M, Bozek J, Lamoy M, et al. Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circ Cardiovasc Imaging. 2011;4:435-443.
11. Patten RD, Hall-Porter MR. Small animal models of heart failure: development of novel therapies, past and present. Circ Heart Fail. 2009;2:138-144.
12. Iversen LL. The uptake of catechol amines at high perfusion concentrations in the rat isolated heart: a novel catechol amine uptake process. Br J Pharmacol Chemother. 1965;25:18-33.
13. Carr EA Jr., Carroll M, Counsell RE, Tyson JW. Studies of uptake of the bretylium analogue, iodobenzyltrimethylammonium iodide, by non-primate, monkey and human hearts. Br J Clin Pharmacol. 1979;8:425-432.
14. Paczkowski FA, Bryan-Lluka LJ, Porzgen P, Bruss M, Bonisch H. Comparison of the pharmacological properties of cloned rat, human, and bovine norepinephrine transporters. J Pharmacol Exp Ther. 1999;290:761-767.
15. Jarrott B. Uptake and metabolism of catecholamines in the perfused hearts of different species. Br J Pharmacol. 1970;38:810-821.
16. Solbach TF, Grube M, Fromm MF, Zolk O. Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization. J Cardiovasc Pharmacol. 2011;58:409-417.
17. Iversen LL, Salt PJ, Wilson HA. Inhibition of catecholamine uptake in the isolated rat heart by haloalkylamines related to phenoxybenzamine. Br J Pharmacol. 1972;46:647-657.
18. Babin-Ebell J, Gliese M. Extraneuronal uptake of noradrenaline in human tissue (uptake2). Heart Vessels. 1995;10:151-153.
19. Grube M, Ameling S, Noutsias M, et al. Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. Am J Pathol. 2011;178:2547-2559.
20. Schroeder C, Jordan J. Norepinephrine uptake mechanisms in cardiovascular disease deserve our attention. J Cardiovasc Pharmacol. 2011;58:406-408.
21. Kopka K, Schober O, Wagner S. 18F-labelled cardiac PET tracers: selected probes for the molecular imaging of transporters, receptors and proteases. Basic Res Cardiol. 2008;103:131-143.
22. Mislankar SG, Gildersleeve DL, Wieland DM, Massin CC, Mulholland GK, Toorongian SA. 6-[18F]fluorometaraminol: a radiotracer for in vivo mapping of adrenergic nerves of the heart. J Med Chem. 1988;31:362-366.
23. Raffel DM, Jung YW, Gildersleeve DL, et al. Radiolabeled phenethylguanidines: novel imaging agents for cardiac sympathetic neurons and adrenergic tumors. J Med Chem. 2007;50:2078-2088.
24. Lazewatsky J, Sinusas A, Brunetti J, et al. Radiation dosimetry of LMI1195, first-inhuman study of a novel F-18 labeled tracer for imaging myocardial innervation [abstract]. J Nucl Med. 2010;51(suppl 2):1432.
25. Liu Y-H, Sr.ivastiva A, Mulnix T, et al. Quantification of normal pattern of regional myocardial uptake of 18F LMI1195, a novel tracer for imaging myocardial sympathetic function: first-in-human study [abstract]. J Nucl Med. 2010;51(suppl 2):1317.
26. Fiebig ER, Trendelenburg U. The neuronal and extraneuronal uptake and metabolism of 3H-(-)-noradrenaline in the perfused rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1978;303:21-35.
27. Zhou Z, Zhen J, Karpowich NK, et al. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science. 2007;317:1390-1393.
28. Rischpler C, Fukushima K, Isoda T, et al. Discrepant uptake of the sympathetic nerve imaging tracers hydroxyephedrine (HED) and metaiodobenzylguanidine (MIBG) in rat hearts. Circulation. March 29, 2013 [Epub ahead of print].
29. Wu X, Kekuda R, Huang W, et al. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998;273:32776-32786.
30. Gründemann D, Schechinger B, Rappold GA, Schomig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci. 1998;1:349-351.
31. Picken GM, Jarrott B. Effects of blockade of extraneuronal uptake on responses to isoprenaline in perfused rat heart. Clin Exp Pharmacol Physiol. 1975;2:249-259.
32. Tumer N, Mortimer ML, Roberts J. Gender differences in the effect of age on adrenergic neurotransmission in the heart. Exp Gerontol. 1992;27:301-307.
33. Iversen LL, Salt PJ. Inhibition of catecholamine uptake-2 by steroids in the isolated rat heart. Br J Pharmacol. 1970;40:528-530.
34. Hayer-Zillgen M, Bruss M, Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002;136:829-836.